3 Asian Stocks That Could Be Trading Below Their True Value In August 2025
Top 10 Undervalued Stocks Based On Cash Flows In Asia
Name
Current Price
Fair Value (Est)
Discount (Est)
Xi'an NovaStar Tech (SZSE:301589)
CN¥155.71
CN¥311.10
49.9%
Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266)
CN¥113.18
CN¥223.99
49.5%
KeePer Technical Laboratory (TSE:6036)
¥3490.00
¥6847.61
49%
Japan Data Science ConsortiumLtd (TSE:4418)
¥1011.00
¥1973.03
48.8%
Heartland Group Holdings (NZSE:HGH)
NZ$0.81
NZ$1.60
49.3%
Guangdong Lyric Robot AutomationLtd (SHSE:688499)
CN¥59.31
CN¥115.92
48.8%
GEM (SZSE:002340)
CN¥6.70
CN¥13.07
48.7%
GCH Technology (SHSE:688625)
CN¥34.60
CN¥68.17
49.2%
EROAD (NZSE:ERD)
NZ$2.31
NZ$4.61
49.9%
Andes Technology (TWSE:6533)
NT$274.00
NT$543.38
49.6%
Click here to see the full list of 268 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Let's explore several standout options from the results in the screener.
Genscript Biotech
Overview: Genscript Biotech Corporation is an investment holding company that manufactures and sells life science research products and services globally, with a market cap of approximately HK$38.65 billion.
Operations: The company's revenue is primarily derived from Life Science Services and Products ($454.95 million), Biologics Development Services ($95.02 million), and Industrial Synthetic Biology Products ($53.69 million).
Estimated Discount To Fair Value: 22%
Genscript Biotech appears undervalued based on cash flows, trading 22% below its estimated fair value of HK$22.72. Recent earnings show significant improvement, with sales reaching US$518.77 million and a reduced net loss of US$25.46 million for H1 2025. The company's revenue is expected to grow at 9.8% annually, outpacing the Hong Kong market's growth rate, while profitability is anticipated within three years, highlighting potential for investors seeking undervalued opportunities in Asia's biotech sector.
The analysis detailed in our Genscript Biotech growth report hints at robust future financial performance.
Click here and access our complete balance sheet health report to understand the dynamics of Genscript Biotech.
Jiangxi Rimag Group
Overview: Jiangxi Rimag Group Co., Ltd. invests in and operates medical imaging centers in China, with a market capitalization of approximately HK$7.26 billion.
Operations: The company's revenue is primarily derived from its Medical Labs & Research segment, totaling CN¥760.59 million.
Estimated Discount To Fair Value: 47.1%
Jiangxi Rimag Group is trading at HK$19.89, significantly below its estimated fair value of HK$37.62, marking it as undervalued based on cash flows. The company forecasts substantial revenue growth of 22.3% annually, surpassing the Hong Kong market average. Recent guidance indicates a remarkable increase in net profit for H1 2025 due to higher customer numbers and reduced expenses. Additionally, a share buyback program aims to enhance shareholder value by improving net asset and earnings per share metrics.
According our earnings growth report, there's an indication that Jiangxi Rimag Group might be ready to expand.
Click to explore a detailed breakdown of our findings in Jiangxi Rimag Group's balance sheet health report.
BuySell TechnologiesLtd
Overview: BuySell Technologies Co., Ltd. operates in Japan's kimono and branded goods reuse sector, with a market cap of ¥110 billion.
Operations: The company generates revenue from its operations in the kimono and branded goods reuse business within Japan.
Estimated Discount To Fair Value: 33.1%
BuySell Technologies Ltd. is trading at ¥3,335, well below its estimated fair value of ¥4,982.57, highlighting its undervaluation based on cash flows. The company's revenue is projected to grow 20.1% annually, outpacing the Japanese market average. Despite recent shareholder dilution due to a follow-on equity offering in June 2025, analysts agree on a potential stock price increase of 36.9%, supported by strong forecasted earnings growth of 19.8% per year above market expectations.
The growth report we've compiled suggests that BuySell TechnologiesLtd's future prospects could be on the up.
Dive into the specifics of BuySell TechnologiesLtd here with our thorough financial health report.
Taking Advantage
Delve into our full catalog of 268 Undervalued Asian Stocks Based On Cash Flows here.
Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Seeking Other Investments?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:1548 SEHK:2522 and TSE:7685.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Israel set to approve 'largest' gas supply deal in its history to Egypt
The Israeli government is set to finalise a major gas supply agreement with Egypt, involving the export of 22% of resources from Leviathan, Israel's largest gas field, and 13% of the country's total natural gas to Cairo over several years. The deal comes after two years of delays and is expected to be signed in the next two weeks. New Energy, a partner in the Leviathan field, described the agreement as the "largest" in the history of the Hebrew state, noting that it will triple Israeli exports by 2028. The company announced that Egypt will buy 130 billion cubic metres of Israeli gas until 2040, worth up to $35 billion (€30bn). The project is an amendment to the 2019 agreement signed by Israeli Prime Minister Benjamin Netanyahu and Egyptian President Abdel Fattah el-Sisi, which stipulated the export of only around 60 billion cubic metres by the early 2020s. The project allows Israel to increase natural gas production and export it to Asian and European markets, while at the same time guaranteeing Egypt a stable supply for its power plants and supporting the country's liquefied natural gas (LNG) sector. Stages of the deal and quantities of gas NewMed Energy (formerly known as Delek Drilling) confirmed that the deal will take place in phases, with Cairo first buying the gas through Egyptian importers Blue Ocean Energy, with 20 billion cubic metres starting in the first half of 2026, and an additional 110 billion cubic metres after the expansion of Leviathan's production is completed, according to the Hebrew newspaper Globes. The company described the deal as pivotal, as it will allow the field's production capacity to expand from 21 billion cubic metres to 23 billion cubic metres per year, strengthening Leviathan's position as one of the most important gas sources in the region. Related Top UK CEOs richer than ever: FTSE 100 boss pay breaks records for third year EU signs €500 million loan to safeguard Ukraine's energy security ahead of winter Export plan for Israel's domestic economy By 2035, Israel will export 60% of the gas produced in the field, while 40% will be allocated to the domestic market to meet the needs of new power plants. In 2024, the field produced about 11 billion cubic metres of gas, 50% of which was exported to Egypt, while the rest was distributed between Israel's domestic economy and Jordan. In terms of gas supply to the Israeli economy, NewMed Energy confirmed that the expansion will ensure that from the 2040s, Leviathan will be Israel's main source of gas, providing the bulk of the country's natural gas consumption until the end of the field's life. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
NBC News
5 hours ago
- NBC News
India and China agree to resume direct flights as Trump shakes up ties
NEW DELHI — India and China agreed on Tuesday to resume direct flights and step up trade and investment flows as the neighbors rebuild ties damaged by a 2020 border clash. The Asian giants are cautiously strengthening ties against the backdrop of President Donald Trump's unpredictable foreign policy, staging a series of high-level bilateral visits. The two countries will resume direct flights and increase trade and investment, including reopening border trade at three designated points, and facilitate in visas, the Indian foreign ministry said. Direct flights have been suspended since the Covid-19 pandemic in 2020. No date was given for their resumption. The latest statements came at the end of Chinese Foreign Minister Wang Yi's two-day visit to New Delhi for the 24th round of talks with Indian National Security Adviser Ajit Doval to resolve their decades-old border dispute. The border talks covered issues related to pulling back troops both countries have amassed on their Himalayan border, delimitation of borders and boundary affairs, the Indian ministry said. Both countries have agreed to set up a working group to consult and coordinate on border affairs to advance demarcation negotiations, a Chinese foreign ministry statement released on Wednesday showed. It said the mechanism will extend talks to cover the eastern and middle sections of the border. Meanwhile another round of talks on the western section will be held as soon as possible, the ministry said. Beijing also said both countries agreed to meet again in China in 2026. 'Stable, predictable, constructive ties between India and China will contribute significantly to regional as well as global peace and prosperity,' Prime Minister Narendra Modi posted on X after meeting Wang. Modi is scheduled to travel to China at the end of this month to take part in the summit of the Shanghai Cooperation Organization — his first visit to the country in more than seven years. A readout from the Chinese foreign ministry said Wang told Doval that 'the stable and healthy development of China-India relations is in the fundamental interests of the two countries' people.' The two sides 'should enhance mutual trust through dialogues and expand cooperation,' Wang said, and should aim for consensus in areas such as border control and demarcation negotiations. India said Foreign Minister Subrahmanyam Jaishankar had underlined in his talks with Wang India's concerns with regard to the mega dam China is building on the Yarlung Zangbo river in Tibet. Yarlung Zangbo becomes the Brahmaputra as it flows into India and Bangladesh, a lifeline for millions. The dam would have implications for lower riparian states and the need for 'utmost transparency' was strongly underlined, New Delhi said. To that, China agreed to share with India emergency hydrological information on relevant rivers on humanitarian principles, China's foreign ministry said. Both sides agreed to engage an expert-level mechanism on cross-border rivers, and maintain communication to renew flood reporting arrangements, the ministry said. Chinese officials had previously said hydropower projects in Tibet will not have a major impact on the environment or on downstream water supplies, but India and Bangladesh have nevertheless raised concerns.
Business Insider
8 hours ago
- Business Insider
Analysts Offer Insights on Consumer Goods Companies: a2 Milk Company (OtherACOPF), Waldencast (WALD) and China Resources Beer (Holdings) Co (OtherCRHKF)
Companies in the Consumer Goods sector have received a lot of coverage today as analysts weigh in on a2 Milk Company (ACOPF – Research Report), Waldencast (WALD – Research Report) and China Resources Beer (Holdings) Co (CRHKF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. a2 Milk Company (ACOPF) In a report released today, Sam Teeger from Citi upgraded a2 Milk Company to Buy, with a price target of A$9.29. The company's shares closed last Tuesday at $5.61. According to Teeger is a 3-star analyst with an average return of 3.1% and a 42.7% success rate. Teeger covers the NA sector, focusing on stocks such as Domino's Pizza Enterprises Limited, Temple & Webster Group Ltd, and ARB Corporation. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for a2 Milk Company with a $5.49 average price target, a -0.2% downside from current levels. In a report issued on August 5, UBS also maintained a Buy rating on the stock. Waldencast (WALD) In a report released yesterday, Jonna Kim from TD Cowen maintained a Hold rating on Waldencast, with a price target of $2.00. The company's shares closed last Tuesday at $1.80. According to Kim is a 4-star analyst with an average return of 15.4% and a 38.9% success rate. Kim covers the NA sector, focusing on stocks such as Victoria's Secret, Bath & Body Works, and Olaplex Holdings. Currently, the analyst consensus on Waldencast is a Moderate Buy with an average price target of $3.23, implying a 65.6% upside from current levels. In a report released yesterday, Raymond James also reiterated a Hold rating on the stock. China Resources Beer (Holdings) Co (CRHKF) In a report released today, Clement Xu from DBS maintained a Buy rating on China Resources Beer (Holdings) Co, with a price target of HK$35.60. The company's shares closed last Tuesday at $3.42. According to Xu is ranked #2592 out of 9989 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for China Resources Beer (Holdings) Co with a $4.56 average price target.
